Recurrent membranous nephropathy with a possible alteration in the etiology: a case report

Ayumi Matsumoto 1, Isao Matsui 1*, Keiji Mano 2, Hitoshi Mizuno 2, Yusuke Katsuma 1, Seiichi Yasuda 1, Karin Shimada 1, Kazunori Inoue 1, Takashi Oki 3, Tadashi Hanai 4, Keiko Kojima 5, Tetsuya Kaneko 2 and Yoshitaka Isaka 1

Abstract

Background: Phospholipase A2 receptor 1 (PLA2R1) and thrombospondin type-1 domain-containing 7A (THSD7A) are the two major pathogenic antigens for membranous nephropathy (MN). It has been reported that THSD7A-associated MN has a higher prevalence of comorbid malignancy than PLA2R1-associated MN. Here we present a case of MN whose etiology might change from idiopathic to malignancy-associated MN during the patient’s clinical course.

Case presentation: A 68-year-old man with nephrotic syndrome was diagnosed with MN by renal biopsy. Immunohistochemistry showed that the kidney specimen was negative for THSD7A. The first course of corticosteroid therapy achieved partial remission; however, nephrotic syndrome recurred 1 year later. Two years later, his abdominal echography revealed a urinary bladder tumor, but he did not wish to undergo additional diagnostic examinations. Because his proteinuria increased consecutively, corticosteroid therapy was resumed, but it failed to achieve remission. Another kidney biopsy was performed and revealed MN with positive staining for THSD7A. PLA2R1 staining levels were negative for both first and second biopsies. Because his bladder tumor had gradually enlarged, he agreed to undergo bladder tumor resection. Pathological examination indicated that the tumor was THDS7A-positive bladder cancer. Subsequently, his proteinuria decreased and remained in remission.

Conclusions: This case suggests that the etiology of MN might be altered during the therapeutic course. Intensive screening for malignancy may be preferable in patients with unexpected recurrence of proteinuria and/or change in therapy response.

Keywords: Membranous nephropathy, Cancer, Thrombospondin type-1 domain-containing 7A

Background

Idiopathic membranous nephropathy (MN) is an immune disease associated with the immune complex. Phospholipase A2 receptor 1 (PLA2R1) and thrombospondin type-1 domain-containing 7A (THSD7A) are recognized as target antigens of MN [1, 2]. Moreover, it is reported that the prevalence of malignancy is higher in patients with THSD7A-associated MN than PLA2R1-associated MN [3]. However, the pathophysiological relationship between the generation of anti-THSD7A antibody and malignancy is unclear. We present a case of MN, in which the etiology might be changed during the clinical and therapeutic course.
Fig. 1 (See legend on next page.)
Case presentation

A 68-year-old man who had hypertension for 14 years was transferred to our facility for the management of nephrotic syndrome with proteinuria at 16.3 g/gCre (Fig. 1A). On admission, he was conscious, and his lower extremities were edematous. His serum creatinine, urea nitrogen and albumin were 0.85 mg/dL, 8 mg/dL and 2.8 g/dL, respectively. To investigate his pathophysiology, a renal biopsy was performed. It revealed that his nephrotic syndrome was caused by stage II MN (Fig. 1B-a,b). Immunohistochemistry showed that the kidney specimen was negative for THSD7A (Fig. 1B-c, d). We shared the diagnosis and therapeutic strategy with him. Based on his agreement, subsequent corticosteroid therapy successfully suppressed his proteinuria to 0.6 g/gCre within 6 months. Every outpatient care visit, he had good adherence to the medication. During the course of corticosteroid therapy, he did not experience any unanticipated event, including abnormal glucose tolerance and exacerbation of hypertension. The remission of proteinuria led to the termination of corticosteroid therapy. At age 69, recurrence of proteinuria (up to 4.9 g/gCre) was observed; however, we hesitated to administer corticosteroid because of unstable angina. At 71 years of age, abdominal ultrasonography revealed a urinary bladder tumor 5 mm in diameter. However, he did not want to undergo further examinations at that time. At 72 years of age, his proteinuria increased up to 12.9 g/gCre. Therefore, we resumed corticosteroid therapy, but remission was not achieved. We performed another renal biopsy, which showed that the patient had MN whose stage has progressed from II to III (Fig. 1B and C). Immunohistochemical staining revealed that the kidney sections were positive for THSD7A in the second biopsy, but not in the first biopsy (Fig. 1B-c, d and C-c, d), while PLA2R1 staining levels were negative for both the first and second biopsies. (Supplemental Figure S1). Because the size of the bladder tumor had increased to 10 mm in diameter, we resected the tumor. Pathological findings indicated that the tumor diagnosis was THSD7A-positive bladder cancer (Fig. 2). Serum levels of anti-PLA2R1 and anti-THSD7A antibodies were not measured in this case due to lack of stored serum samples. Although proteinuria temporarily increased after the surgery, the proteinuria level decreased to 0.3 g/gCre within 12 months following the tumor resection.
Discussion and conclusion
Herein we present a case of THSD7A-associated MN. PLA2R1 and THSD7A are now recognized as target antigens of MN [1, 2]. The prevalence of serum anti-PLA2R1 and anti-THSD7A antigens are reported to be 52–98% and 2.5–9.1%, respectively [4]. The etiology of THSD7A-associated MN is reportedly different from that of PLA2R1-associated MN in terms of malignant tumor involvement. The prevalence of malignant tumors was 5.4% in PLA2R1-positive MN and 20–33% in THSD7A-associated MN [3].

In this case, though the first kidney biopsy showed normal immunohistochemical staining for THSD7A, the second biopsy showed enhanced staining. Furthermore, the comorbid bladder tumor tissue was positive for THSD7A, while surrounding normal bladder tissue, obtained at the time of cancer resection surgery, showed a negative stain for THSD7A. Although we could not determine serum levels of anti-PLA2R1 and anti-THSD7A antibodies due to lack of stored serum samples, various studies have revealed that renal immunostaining patterns of PLA2R1 and THSD7A in the presence of circulating anti-PLA2R and anti-THSD7A antibodies are different from those in the absence of these antibodies [2, 5–7] The findings of the current case suggest that the incipient nephrotic syndrome was led by idiopathic MN, and the recurrent nephrotic syndrome was led by malignancy-associated MN. The different responses to corticosteroid therapies in the incipient and the recurrent nephrotic syndrome also suggest that the etiology of MN in this case might be altered during the therapeutic course. However, there remains a possibility that both the incipient and the recurrent MN were caused by bladder tumor. The production of more THSD7A antigens in the gradually enlarged bladder tumor might cause the enhanced staining of THSD7A in the second kidney biopsy. The analysis of IgG subclasses would help to distinguish primary MN from secondary MN. However, we could not determine IgG subclasses because fresh-frozen kidney tissues are not stored. It has been reported that the dominant IgG subclasses did not change over time in recurrent MN in transplanted kidney, suggesting that the MN etiology under transplantation setting might not change [8]. Further studies are required to clarify whether cancer can alter the etiology of recurrent MN.

Based on similar clinical findings in previously published reports, the causal relationship between malignant tumor and MN has been discussed [3, 9]. We have reported that vascular endothelial growth factor-A (VEGF-A) induces THSD7A expression in human umbilical vein endothelial cells [10]. Malignant tumors are known as neovascularization-rich tissue, where VEGF-A plays an essential role in its pathogenesis [11]. This fact may explain the positive stain for THSD7A only in the tumor tissue but not in the normal tissue in this case. Although the precise mechanisms of THSD7A-associated MN remain unclear, there might be a hypothesis that VEGF-A induces THSD7A expression as an immunogenic protein at the tumor loci. Further investigation is required to warrant this hypothesis.

To the best of our knowledge, this is the first report showing that a malignant tumor might alter the etiology of recurrent MN. The therapeutic course supports the hypothesis that THSD7A-positive bladder cancer was responsible for developing THSD7A-positive MN. Intensive cancer screening may have to be performed upon a finding of THSD7A-positive MN. Furthermore, it might be advisable to perform repeat renal biopsy when unexpected recurrence of proteinuria occurred or a change in therapeutic response was observed.

Methods
Biopsy samples were fixed in a 10% neutral buffered formalin solution, dehydrated in an increasing ethanol concentration solution series, and embedded in paraffin. Paraffin-embedded sections were stained with periodic acid methenamine silver using standard procedures. Antibodies against specific molecules were obtained as PLA2R1 (HPA012657; Sigma-Aldrich, St. Louis, MO, USA) and THSD7A (HPA000923; Sigma-Aldrich, St. Louis, MO, USA). Immunohistological staining was performed on freshly-cut specimens using standard methods [12–19].

Abbreviations
MN: Membranous nephropathy; PLA2R1: Phospholipase A2 receptor 1; THSD7A: Thrombospondin type-1 domain-containing 7A; VEGF-A: Vascular endothelial growth factor-A

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12882-021-02457-0.

Additional file 1: Supplemental Figure S1. Immunohistochemical analysis for PLA2R1 on (A) a specimen from the first biopsy and (B) a specimen from the second biopsy. (scale bars: (a) 50 μm and (b) 20 μm).

Acknowledgements
Not applicable.

Authors’ contributions
AM and IM wrote this manuscript. KM, TO, TH, KK, HM, and TK contributed to the diagnosis and therapeutic course. YK, SY, KS, KI, and YI contributed to the immunohistological analysis. All authors read and approved the final manuscript.

Funding
The authors have no funding to report.

Availability of data and materials
All data analyzed during this study are included in this manuscript.
Declarations

Ethics approval and consent to participate
Osaka University Clinical Research Review Committee does not require ethical approval for reporting individual cases or case series. Written informed consent to participate was obtained from the patient.

Consent for publication
Written informed consent for publication was obtained from the patient.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Nephrology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. 2Department of Pathology, Daini Osaka Police Hospital, 2-6-40, Karasuga-tsuji, Tennoji, Osaka 543-8922, Japan. 3Department of Urology, Mimihara General Hospital, 4-465, kyowacho, Sakai-ku, Sakai, Osaka 590-8505, Japan. 4Department of Urology, Daini Osaka Police Hospital, 2-6-40, Karasuga-tsuji, Tennoji, Osaka 543-8922, Japan. 5Department of Pathology, Daini Osaka Police Hospital, 2-6-40, Karasuga-tsuji, Tennoji, Osaka 543-8922, Japan.

Received: 29 January 2021 Accepted: 24 June 2021

Published online: 06 July 2021

References
1. Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21. https://doi.org/10.1056/NEJMoa0810457.

2. Tomas NM, Beck LH, Meyer-Schwesinger C, Seitz-Poliski B, Ma H, Zahner G, et al. Thrombospondin Type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–87. https://doi.org/10.1056/NEJMoa1409354.

3. Hoxha E, Beck LH, Wiech T, Tomas NM, Probst C, Mindorf S, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2017;28(2):520–31. https://doi.org/10.1681/ASN.20161001050.

4. Iwakura T, Ohashi N, Kato A, Baba S, Yasuda H. Prevalence of enhanced granular expression of thrombospondin Type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy. PLoS One. 2015;10(9):e0138841. https://doi.org/10.1371/journal.pone.0138841.

5. Debier H, Ronco P. PLA 2 R autoantibodies and PLA 2 R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689–90. https://doi.org/10.1056/NEJMoa1101678.

6. Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H. Kidney biopsy is a novel potential intercellular communications in embryonic kidney. Sci Rep. 2021;11(1):73. https://doi.org/10.1038/s41598-020-80154-y.

7. Matsui I, Oka T, Kusunoki Y, Yasuda S, Shimada K, et al. Single cell RNA sequencing uncovers cellular developmental sequences and temporal IgG subtype changes in recurrent idiopathic membranous nephropathy. Am J Transplant. 2016;16(10):2964–72. https://doi.org/10.1111/ajt.13906.

8. Kattah AG, Alexander MP, Angiol A, De Viere AS, Sethi S, Cosio FG, et al. Temporal IgG subtype changes in recurrent idiopathic membranous nephropathy. Am J Transplant. 2016;16(10):2964–72. https://doi.org/10.1111/ajt.13906.

9. Hoxha E, Wiech T, Stahl PR, Zahner G, Tomas NM, Meyer-Schwesinger C, et al. A mechanism for cancer-associated membranous nephropathy. N Engl J Med. 2016;374(20):1995–6. https://doi.org/10.1056/NEJMct1511702.

10. Matsumoto A, Matsui I, Namba T, Sakaguchi Y, Mizuno H, Shirayama Y, et al. VEGF-A links Angiolympoid hyperplasia with eosinophilia (ALHE) to THSD7A membranous nephropathy: a report of 2 cases. Am J Kidney Dis. 2019;73(7):880–5. https://doi.org/10.1053/j.ajkd.2018.10.009.

11. Carmeliet P. VEGF as a key mediator of angiogenesis in Cancer. Oncology. 2005;69(3):34–10. https://doi.org/10.1159/000088478.

12. Matsui I, Hamano T, Mikami S, Inoue K, Shimomura A, Nagasawa Y, et al. Retention of fetuin-a in renal tubular lumen protects the kidney from nephrocalcinosis in rats. AJP Ren Physiol. 2013;304(6):F751–60. https://doi.org/10.1152/ajpregu.00329.2012.

13. Mori D, Matsui I, Shimomura A, Hashimoto N, Matsumoto A, Shimada K, et al. Protein carbamylation exacerbates vascular calcification. Kidney Int. 2018;94(1):72–90. https://doi.org/10.1016/j.kint.2018.01.033.

14. Hashimoto N, Matsui I, Ishiuka S, Inoue K, Matsumoto A, Shimada K, et al. Lithocholic acid increases intestinal phosphate and calcium absorption in a vitamin D receptor dependent but transcellular pathway independent manner. Kidney Int. 2020;97(6):1164–80. https://doi.org/10.1016/j.kint.2020.01.052.

15. Kusunoki Y, Matsui I, Hamano T, Shimomura A, Mori D, Yonemoto S, et al. Excess 25-hydroxyVitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype. Kidney Int. 2015;88(5):1013–29. https://doi.org/10.1016/j.kint.2015.210.

16. Shimomura A, Matsui I, Hamano T, Ishimoto T, Katou Y, Takehana K, et al. Dietary L-lysine prevents arterial calcification in adenine-induced uremic rats. J Am Soc Nephrol. 2011;22(9):1954–65. https://doi.org/10.1681/ASN2011090906.

17. Inoue K, Matsui I, Hamano T, Okuda K, Tsukamoto Y, Matsumoto A, et al. Maxacalcitol (22-Oxacalcitriol (OCT)) retards progression of left ventricular hypertrophy with renal dysfunction through inhibition of calcineurin-nrf2 activity. Cardiovasc Drugs Ther. 2020. https://doi.org/10.1007/s10557-020-07111-9.

18. Matsui I, Matsumoto A, Inoue K, Katsuma Y, Yasuda S, Shimada K, et al. Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23. Kidney Int. 2019;62:160–71. https://doi.org/10.1016/j.kint.2018.02.018.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.